Navigation Links
Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care

BETHESDA, Md., Nov. 1, 2011 /PRNewswire-USNewswire/ --  For the first time, a drug that's designed to treat the underlying cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review by the U.S. Food and Drug Administration for possible approval in 2012. This milestone comes as the largest international gathering of cystic fibrosis experts kicks off in Anaheim, Calif., Nov. 3 – 5, 2011.

Kalydeco (kuh-LYE-deh-koh) is designed to address the genetic defect in cystic fibrosis in select patient groups, unlike all CF therapies now on the market, which only treat symptoms of the disease. It was formerly known as VX-770.

At the 25th annual North American Cystic Fibrosis Conference (NACFC), physicians, scientists and clinicians will present data and workshops on the latest advancements in CF related to research, care and drug development, including new clinical data on Kalydeco.

Key conference topics include:

  • Emerging therapies that target the core defect in CF.
  • Partnering with patients and families to improve care.
  • Best practices and mentoring for adult CF care providers.
  • Effective treatment and management of lung infections.

Cystic fibrosis is a genetic disease that causes life-threatening lung infections and premature death. An estimated 30,000 people in the United States, and about 70,000 people worldwide, have CF. Ten million Americans are symptomless carriers of a defective CF gene. Fifty years ago, most children with CF died before reaching kindergarten. Today, because of Cystic Fibrosis Foundation-supported drug research and care, many people with CF are living into their 30s, 40s and beyond.

The 25th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists and clinicians.

Thursday, Nov. 3 – Saturday, Nov. 5, 2011, at the Anaheim Convention Center, Anaheim, California.

Thursday, Nov. 3, 4:20 p.m. – Marcus A. Mall, M.D., University of Heidelberg, Heidelberg, Germany: "CFTR Modulation – 25 Years of NACFC Progress."

Friday, Nov. 4, 9:00 a.m. – Garry R. Cutting, M.D., and Patrick R. Sosnay, M.D., Johns Hopkins University, Baltimore, Maryland: "CFTR2 – A Research and Clinical Practice Tool."

Saturday, Nov. 5, 9:00 a.m. – Patrick A. Flume, M.D., Medical University of South Carolina, Charleston, South Carolina: "Pulmonary Exacerbations."

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to

SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
5. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
6. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
7. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
8. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
11. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
Post Your Comments:
(Date:10/13/2015)... 2015  Measurement in accountable care programs is ... incentives, but gaps in measurement can result in ... systems. A new, peer-reviewed study published in ... explores measurement gaps for high-priority conditions and ... --> --> "These gaps ...
(Date:10/13/2015)... -- ) has announced ... markets for Meniscal Repair - 16 Countries (2010-2021)" ... ) has announced the addition of the ... - 16 Countries (2010-2021)" report to their ... ) has announced the addition of the ...
(Date:10/13/2015)... , Oct. 13, 2015   Vigilant Biosciences, ... solutions that aid in the early detection and intervention ... awarded Vigilant,s founder and CEO, Matthew H.J. Kim ... Award, which recognizes an entrepreneur who has made extraordinary ... life sciences industry in the leadership of a ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... , ... In an age where the cost of energy is rising, ... than in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 percent ... percent. , According to Facilities Management Administrative Director Dieter Reichmann, this is the ...
(Date:10/13/2015)... LOUIS and CHENNAI, India (PRWEB) , ... October 13, 2015 , ... ... development of advanced camera solutions, today announced See3CAM_CU40, the industry’s first RGB-IR ... MIPI CSI-2 module. See3CAM_CU40, a new member of e-con’s See3CAM family of UVC USB ...
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 ... ... published an in-depth review of Anik Singal's newly launched "Publish Academy" training ... a digital publishing business opened for enrollment today, and marketers around the Internet ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... that targets the unique health needs of new moms. Postnatal Omega-3, which ... ( ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... of telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership ... for their regional telehealth summits for Fall 2015. , Each of the ...
Breaking Medicine News(10 mins):